In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cardiome enters $68mm anti-arrhythmic deal with Fujisawa; ends

Executive Summary

Cardiovascular disease company Cardiome Pharma and Fujisawa Healthcare have entered into an agreement to co-develop an intravenous formulation of Cardiome's Phase III RSD1235 anti-arrhythmic drug candidate. The deal could be worth up to $68mm ($Cdn90mm).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies